CUV Overzicht aandelen
Clinuvel Pharmaceuticals Limited, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met genetische, metabole, systemische en levensbedreigende aandoeningen in Australië, Europa, de Verenigde Staten, Zwitserland en internationaal.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Clinuvel Pharmaceuticals Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | AU$13.73 |
| 52 Week Hoogtepunt | AU$18.20 |
| 52 Week Laag | AU$12.96 |
| Bèta | 0.92 |
| 11 maand verandering | -2.56% |
| 3 maanden verandering | 0% |
| 1 Jaar Verandering | -11.87% |
| 33 jaar verandering | -57.82% |
| 5 jaar verandering | -56.88% |
| Verandering sinds IPO | 1,273.00% |
Recent nieuws en updates
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Rendement voor aandeelhouders
| CUV | AU Biotechs | AU Markt | |
|---|---|---|---|
| 7D | -5.3% | -3.7% | -1.1% |
| 1Y | -11.9% | 19.0% | 16.1% |
Rendement versus industrie: CUV underperformed the Australian Biotechs industry which returned 19% over the past year.
Rendement versus markt: CUV underperformed the Australian Market which returned 16.1% over the past year.
Prijsvolatiliteit
| CUV volatility | |
|---|---|
| CUV Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stabiele aandelenkoers: CUV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatiliteit in de loop van de tijd: CUV's weekly volatility (5%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met genetische, metabole, systemische en levensbedreigende aandoeningen in Australië, Europa, de Verenigde Staten, Zwitserland en internationaal. De belangrijkste kandidaat is SCENESSE, een systemisch fotoprotectief geneesmiddel voor de preventie van fototoxiciteit bij volwassen patiënten met erytropoëtische protoporfyrie (EPP). De pijplijnproducten van het bedrijf omvatten CUV9900 en Parvysmelanotide (VLRX001), beide analogen voor alfa-melanocyten stimulerend hormoon; en PRÉNUMBRA, een vloeibare injecteerbare formulering van afamelanotide.
Clinuvel Pharmaceuticals Limited Samenvatting
| CUV fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | AU$685.77m |
| Inkomsten(TTM) | AU$35.64m |
| Inkomsten(TTM) | AU$88.18m |
19.2x
Koers/Winstverhouding7.8x
P/S-verhoudingIs CUV overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CUV resultatenrekening (TTM) | |
|---|---|
| Inkomsten | AU$88.18m |
| Kosten van inkomsten | AU$7.73m |
| Brutowinst | AU$80.45m |
| Overige uitgaven | AU$44.81m |
| Inkomsten | AU$35.64m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.71 |
| Brutomarge | 91.23% |
| Nettowinstmarge | 40.41% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CUV op de lange termijn?
Bekijk historische prestaties en vergelijking